Abstract 2128P
Background
Exercise (EX) is associated with a reduction in mortality and recurrence risk in patients (pts) with cancer and may help pts cope with treatment side effects and improve their quality of life. This study aims to explore the role of oncologists in promoting exercise in the oncological context.
Methods
A self-administered, anonymous questionnaire was proposed to pts visiting the outpatients’ facilities at the Oncology Unit of Verona Hospital. The questionnaire assessed demographic, health, and EX parameters. EX variables, drawn from a prior study, included: the level evaluated with Godin’s Leisure Time Exercise Questionnaire and information regarding: whether EX was discussed; whether oncologists assess, advise, reinforce, and refer (AARR process) pts effort to exercising; and whether pts preferred that EX be discussed. Descriptive statistic, presented as mean, frequencies, and percentages, was applied.
Results
Overall, 202 pts completed the survey (76% response rate). The most frequent tumor types were upper gastrointestinal (45%) and breast (19%). Only 9% of pts were sufficiently active. Regarding the actual EX discussion, 29% of pts reported that their oncologist started a discussion about EX, 12% initiated the discussion themselves, and 60% referred that the issue was not considered. Concerning the AARR process, 26% of pts declared that their oncologists assessed their EX level, 14% and 33% received advice or reinforcement to increase their EX, respectively, and 9% were referred to an appropriate EX service. On the other hand, the items related to the preferred modality of EX discussion showed that 69% of pts thought that oncologists should initiate an EX-discussion, 3% that only pts should start the discussion, and 23% thought that EX should not be discussed.
Conclusions
Our preliminary results show that most pts are insufficiently active, and the majority stated that they did not discuss EX. Nevertheless, most pts would prefer that oncologists initiate a discussion about EX. According to these findings, strategies to support clinicians in promoting EX to their pts should be developed. Further pts’ enrollment is currently ongoing and a more updated analysis will be available for presentation at the ESMO Congress.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06